A Single Nucleotide Polymorphism in the MMP9 Promoter Affects Lung Cancer and Clinicopathological Properties in Iranian Population

Somayeh Taghvaei*; Leila Saremi; Majid Motovali-bashi

**Somayeh Taghvaei*, Leila Saremi and Majid Motovali-bashi**

Volume2-Issue12
Dates: Received: 2021-12-15 | Accepted: 2021-12-27 | Published: 2021-12-29
Pages: 1274-1282

Abstract

Background: Lung cancer is the most common cancer with 2,206,771 new cases in 2020 in worldwide. MMP9 is a member of matrix metalloproteinase family that is also known as gelatinase B or IV type collagenase (92KD). MMP9 through degrading of Extracellular Matrix (ECM) and releasing of growth factors has fundamental role in the tumorigenesis process. The C -1562 T SNP in the MMP9 promoter increases MMP9 expression and susceptibility to lung cancer. Then, the aim of this present case-control study was to investigate whether genetic variations of the MMP9 gene may constitute markers for lung cancer risk in males and in positive family history people in Iran.

Methods: This is a case-control study including 120 lung cancer patients and 100 healthy controls.

Polymorphism in the C -1562 T region was genotyped by PCR-RFLP assay. Odds Ratio (ORs) and 95% Confidence Intervals (CIs) were estimated by chi-square test from comparison of genotypes between lung cancer patients and healthy controls, using SPSS version 26.0. T-test and Image J software was also used.

Results: The distribution of C-1562T genotype was significantly associated with the risk of lung cancer (Odds Ratio [OR] = 2.56, 95% Confidence Interval [CI] = 0.06-23.82). The further stratification analyses shown that males and patients with positive family history may increase risk of lung cancer.

Conclusion: Our results indicated that the MMP9 C -1562 T polymorphism affects risk of lung cancer. In addition, men with T allele (OR = 3.94, CI = 1.47-10`.55) and patients with TT genotype and family history (OR = 2.18, CI = 1.03-4.59) exposure to higher risk of lung cancer.

FullText HTML FullText PDF DOI: 10.37871/jbres1382

Certificate of Publication

Copyright

How to cite this article

Taghvaei S, Saremi L, Motovali-Bashi M. A Single Nucleotide Polymorphism in the MMP9 Promoter Affects Lung Cancer and Clinicopathological Properties in Iranian Population. J Biomed Res Environ Sci. 2021 Dec 29; 2(12): 1274-1282. doi: 10.37871/jbres1382, Article ID: JBRES1382, Available at: https://www.jelsciences.com/articles/jbres1382.pdf

Subject area(s)

University/Institute

Islamic Azad University

References

Chaudhary AK, Singh M, Bharti AC, Singh M, Shukla S, Singh AK, Mehrotra R. Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter (-1171 5A->6A) polymorphism in oral submucous fibrosis and head and neck lesions. BMC Cancer. 2010 Jul 14;10:369. doi: 10.1186/1471-2407-10-369. PMID: 20630073; PMCID: PMC2912870.
Zhang LF, Zhu LJ, Zhang W, Yuan W, Song NH, Zuo L, Mi YY, Wang ZJ, Zhang W. MMP-8 C-799 T, Lys460Thr, and Lys87Glu variants are not related to risk of cancer. BMC Med Genet. 2019 Oct 21;20(1):162. doi: 10.1186/s12881-019-0890-z. PMID: 31638929; PMCID: PMC6805444.
Matsumura S, Oue N, Kitadai Y, Chayama K, Yoshida K, Yamaguchi Y, Toge T, Imai K, Nakachi K, Yasui W. A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol. 2004 May;130(5):259-65. doi: 10.1007/s00432-004-0543-1. Epub 2004 Feb 18. PMID: 14986114.
Löffek S, Schilling O, Franzke CW. Series "matrix metalloproteinases in lung health and disease": Biological role of matrix metalloproteinases: a critical balance. Eur Respir J. 2011 Jul;38(1):191-208. doi: 10.1183/09031936.00146510. Epub 2010 Dec 22. PMID: 21177845.
Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, Xiong W, Xu Y, Zhao J. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 2013 Mar 15;517(1):65-71. doi: 10.1016/j.gene.2012.12.085. Epub 2013 Jan 9. PMID: 23313298.
Wang WL, Chang WL, Yeh YC, Lee CT, Chang CY, Lin JT, Sheu BS. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract. Mol Carcinog. 2013 Jun;52(6):438-45. doi: 10.1002/mc.21874. Epub 2012 Jan 12. PMID: 22241750.
Yeh YC, Sheu BS, Cheng HC, Wang YL, Yang HB, Wu JJ. Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci. 2010 Jun;55(6):1649-57. doi: 10.1007/s10620-009-0926-x. Epub 2009 Aug 19. PMID: 19690958.
Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, Mueller MM. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010 Jul;31(7):1175-84. doi: 10.1093/carcin/bgp248. Epub 2009 Nov 5. PMID: 19892798; PMCID: PMC2893794.
Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40(6-7):1362-78. doi: 10.1016/j.biocel.2007.12.006. Epub 2007 Dec 24. PMID: 18258475.
Wang Y, Fang S, Wei L, Wang R, Jin X, Wen D, Li Y, Guo W, Wang N, Zhang J. No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer. 2005 Aug;49(2):155-61. doi: 10.1016/j.lungcan.2005.04.006. PMID: 15949868.
Huang H, Zhao W, Tang Z, Yang S, Wu Z, Zhao S, Cui W, Mu Y, Chu M, Li K. Characterization of porcine MMP-2 and its association with immune traits. Gene. 2009 Apr 15;435(1-2):63-71. doi: 10.1016/j.gene.2009.01.002. Epub 2009 Jan 20. PMID: 19393189.
Decock J, Paridaens R, Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet. 2008 Mar;73(3):197-211. doi: 10.1111/j.1399-0004.2007.00946.x. Epub 2007 Dec 29. PMID: 18177467.
Xu T, Zhang S, Qiu D, Li X, Fan Y. Association between matrix metalloproteinase 9 polymorphisms and breast cancer risk: An updated meta-analysis and trial sequential analysis. Gene. 2020 Oct 30;759:144972. doi: 10.1016/j.gene.2020.144972. Epub 2020 Jul 30. PMID: 32739585.
Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol. 2003 Jan;28(1):12-24. doi: 10.1165/rcmb.2002-0166TR. PMID: 12495928.
Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89. doi: 10.1016/j.bbcan.2004.09.006. PMID: 15588763.
Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007 Oct;26(8):587-96. doi: 10.1016/j.matbio.2007.07.001. Epub 2007 Jul 7. PMID: 17669641; PMCID: PMC2246078.
Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev. 2007 Jan;87(1):69-98. doi: 10.1152/physrev.00022.2006. PMID: 17237343; PMCID: PMC2656382.
Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000 Jan 15;14(2):163-76. PMID: 10652271; PMCID: PMC316345.
Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med (Maywood). 2006 Jan;231(1):20-7. doi: 10.1177/153537020623100103. PMID: 16380641.
Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res. 2003 Feb;9(2):551-4. PMID: 12576417.
Khalid A, Javaid MA. Matrix metalloproteinases: new targets in cancer therapy. J Cancer Sci Ther. 2016;8(6):143-153. doi: 10.4172/1948-5956.1000406.
Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y, Li D, Yan L, Liu H, Xu Z. Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 2018 Jan 4;13(1):e0190725. doi: 10.1371/journal.pone.0190725. PMID: 29300772; PMCID: PMC5754131.
Gong L, Wu D, Zou J, Chen J, Chen L, Chen Y, Ni C, Yuan H. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016 Apr 5;7(14):18458-68. doi: 10.18632/oncotarget.7607. PMID: 26918342; PMCID: PMC4951301.
Jafari M, et al. Association of MMP 9-1562 C/T single nucleotide polymorphism with the susceptibility to lung cancer disease in South Iranian population. Journal of Advances in Medicine and Medical Research, 2014;2494-2502.
Minematsu N, Nakamura H, Tateno H, Nakajima T, Yamaguchi K. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun. 2001 Nov 23;289(1):116-9. doi: 10.1006/bbrc.2001.5936. PMID: 11708786.
Yang CH, Chang HW, Cheng YH, Chuang LY. Novel generating protective single nucleotide polymorphism barcode for breast cancer using particle swarm optimization. Cancer Epidemiol. 2009 Aug;33(2):147-54. doi: 10.1016/j.canep.2009.07.001. Epub 2009 Jul 28. PMID: 19679063.
Yeh YC, Sheu BS. Matrix metalloproteinases and their inhibitors in the gastrointestinal cancers: current knowledge and clinical potential. Metalloproteinases In Medicine. 2014;1:3-13. doi: 10.2147/MNM.S51000.
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J, Wang H, Yu L, Huang H, Qiu Y, Wei G, Fang Q, Zhou J, Sheng J, Liang T, Li L. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(1):147-157. Chinese. doi: 10.3785/j.issn.1008-9292.2020.02.02. PMID: 32096367.
Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W. A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol. 2005 Jan;131(1):19-25. doi: 10.1007/s00432-004-0621-4. Epub 2004 Sep 30. PMID: 15565457.
Sadeghi M, Motovali-Bashi M, Hojati Z. MMP-9 promoter polymorphism associated with tumor progression of breast cancer in Iranian population. International journal of integrative biology. 2009;6(1):33-37. https://bit.ly/3eqQIJZ
Park KS, Kim SJ, Kim KH, Kim JC. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2011 Feb;26(2):391-7. doi: 10.1111/j.1440-1746.2010.06504.x. PMID: 21261731.
Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L. TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet. 2007 Jan 1;172(1):38-44. doi: 10.1016/j.cancergencyto.2006.07.014. PMID: 17175378.
Hajihoseini S, et al. Prognostic significance of MMP2 and MMP9 functional promoter single nucleotide polymorphisms in head and neck squamous cell carcinoma. Iranian Journal of Basic Medical Sciences. 2011; 14(2):137-144.
Radunovic M, Nikolic N, Milenkovic S, Tomanovic N, Boricic I, Dimitrijevic M, Novakovic I, Basta-Jovanovic G. The MMP-2 and MMP-9 promoter polymorphisms and susceptibility to salivary gland cancer. J BUON. 2016 May-Jun;21(3):597-602. PMID: 27569079.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215. doi: 10.1093/nar/16.3.1215. PMID: 3344216; PMCID: PMC334765.
Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, Gari MA, Chaudhary AG, Abuzenadah AM, Al-Qahtani MH. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014 Mar;34(3):1355-66. PMID: 24596383.
Sun DW, Zhang YY, Qi Y, Zhou XT, Lv GY. Prognostic significance of MMP-7 expression in colorectal cancer: a meta-analysis. Cancer Epidemiol. 2015 Apr;39(2):135-42. doi: 10.1016/j.canep.2015.01.009. Epub 2015 Feb 9. PMID: 25677090.
Somiari SB, Shriver CD, Heckman C, Olsen C, Hu H, Jordan R, Arciero C, Russell S, Garguilo G, Hooke J, Somiari RI. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer. Cancer Lett. 2006 Feb 20;233(1):98-107. doi: 10.1016/j.canlet.2005.03.003. PMID: 16473671.
Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2006 May 1;11:1696-701. doi: 10.2741/1915. PMID: 16368548.
Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999 Apr 13;99(14):1788-94. doi: 10.1161/01.cir.99.14.1788. PMID: 10199873.
Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, Huang LQ, Huang Q, Han Y, Hu B, Hu F, Li BH, Li YR, Liang K, Lin LK, Luo LS, Ma J, Ma LL, Peng ZY, Pan YB, Pan ZY, Ren XQ, Sun HM, Wang Y, Wang YY, Weng H, Wei CJ, Wu DF, Xia J, Xiong Y, Xu HB, Yao XM, Yuan YF, Ye TS, Zhang XC, Zhang YW, Zhang YG, Zhang HM, Zhao Y, Zhao MJ, Zi H, Zeng XT, Wang YY, Wang XH; , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020 Feb 6;7(1):4. doi: 10.1186/s40779-020-0233-6. PMID: 32029004; PMCID: PMC7003341.
Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer. 2000 Apr 15;86(2):204-7. doi: 10.1002/(sici)1097-0215(20000415)86:2<204::aid-ijc9>3.0.co;2-6. PMID: 10738247.
Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002 Dec;37(6):375-536. doi: 10.1080/10409230290771546. PMID: 12540195.
Benbow U, Brinckerhoff CE. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 1997 Mar;15(8-9):519-26. doi: 10.1016/s0945-053x(97)90026-3. PMID: 9138284.
Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003 Jan 16;303:11-34. doi: 10.1016/s0378-1119(02)01156-3. PMID: 12559563.
Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, Valente AJ. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem. 2006 Jun 2;281(22):15099-109. doi: 10.1074/jbc.M600200200. Epub 2006 Mar 22. PMID: 16554298.
Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res. 2004 Nov 15;10(22):7621-8. doi: 10.1158/1078-0432.CCR-04-1061. PMID: 15569994.
Motovali-Bashi M, Sadeghi M, Hemmati S. Serum MMP-9 level associated with initiation and progression steps of breast cancer in the Iranian population. Reprod Sci. 2010 Jun;17(6):585-9. doi: 10.1177/1933719110364418. Epub 2010 Mar 25. PMID: 20338991.
Padala C, Tupurani MA, Puranam K, Gantala S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi RK, Kupsal K, Nanchari SR, Chavan U, Chinta SK, Mukta S, Satti V, Hanumanth SR. Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 2017 Sep 29;12(9):e0184448. doi: 10.1371/journal.pone.0184448. PMID: 28961241; PMCID: PMC5621673.
Hemati S, et al. Higher plasma MMP-9 level in breast cancer patients with MMP-9 promoter T allele. Journal of Biological Research. 2010;13:113.
Owyong M, Chou J, van den Bijgaart RJ, Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C, Hadler-Olsen E, Headley M, Lin C, Wang CY, Sagi I, Werb Z, Plaks V. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Sci Alliance. 2019 Nov 14;2(6):e201800226. doi: 10.26508/lsa.201800226. PMID: 31727800; PMCID: PMC6856766.
Wieczorek E, Reszka E, Jablonowski Z, Jablonska E, Krol MB, Grzegorczyk A, Gromadzinska J, Sosnowski M, Wasowicz W. Genetic polymorphisms in matrix metalloproteinases (MMPs) and tissue inhibitors of MPs (TIMPs), and bladder cancer susceptibility. BJU Int. 2013 Dec;112(8):1207-14. doi: 10.1111/bju.12230. Epub 2013 Jul 2. PMID: 23819551.
Zhang LF, Mi YY, Cao Q, Wang W, Qin C, Wei JF, Zhou YJ, Li YF, Tang M, Liu WM, Zhang W, Zou JG. Update analysis of studies on the MMP-9 -1562 C>T polymorphism and cancer risk. Mol Biol Rep. 2012 Apr;39(4):3435-41. doi: 10.1007/s11033-011-1115-5. Epub 2011 Jun 30. PMID: 21717058.
Zhou P, Du LF, Lv GQ, Yu XM, Gu YL, Li JP, Zhang C. Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2011 Jun;127(3):813-8. doi: 10.1007/s10549-010-1294-0. Epub 2010 Dec 15. PMID: 21161369.
Tao L, Li Z, Lin L, Lei Y, Hongyuan Y, Hongwei J, Yang L, Chuize K. MMP1, 2, 3, 7, and 9 gene polymorphisms and urinary cancer risk: a meta-analysis. Genet Test Mol Biomarkers. 2015 Oct;19(10):548-55. doi: 10.1089/gtmb.2015.0123. Epub 2015 Aug 24. PMID: 26301605; PMCID: PMC4599389.
Peng B, Cao L, Ma X, Wang W, Wang D, Yu L. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010 Jul;25(4):371-9. doi: 10.1093/mutage/geq015. Epub 2010 Apr 1. PMID: 20360147.
Bayramoglu A, Gunes HV, Metintas M, Değirmenci I, Mutlu F, Alataş F. The association of MMP-9 enzyme activity, MMP-9 C1562T polymorphism, and MMP-2 and -9 and TIMP-1, -2, -3, and -4 gene expression in lung cancer. Genet Test Mol Biomarkers. 2009 Oct;13(5):671-8. doi: 10.1089/gtmb.2009.0053. PMID: 19814619.
Yan Y, Liang H, Li T, Li M, Li R, Qin X, Li S. The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis. Tumour Biol. 2014 Apr;35(4):3047-52. doi: 10.1007/s13277-013-1395-6. Epub 2014 Jan 5. PMID: 24390660; PMCID: PMC3980037.
Sauter W, Rosenberger A, Beckmann L, Kropp S, Mittelstrass K, Timofeeva M, Wölke G, Steinwachs A, Scheiner D, Meese E, Sybrecht G, Kronenberg F, Dienemann H; LUCY-Consortium, Chang-Claude J, Illig T, Wichmann HE, Bickeböller H, Risch A. Matrix metalloproteinase 1 (MMP1) is associated with early-onset lung cancer. Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1127-35. doi: 10.1158/1055-9965.EPI-07-2840. PMID: 18483334.
Su L, Zhou W, Asomaning K, Lin X, Wain JC, Lynch TJ, Liu G, Christiani DC. Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis. 2006 May;27(5):1024-9. doi: 10.1093/carcin/bgi283. Epub 2005 Nov 25. PMID: 16311244.
Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 2001 Nov 1;61(21):7825-9. PMID: 11691799.
Hulboy DL, Rudolph LA, Matrisian LM. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod. 1997 Jan;3(1):27-45. doi: 10.1093/molehr/3.1.27. PMID: 9239706.
Rahimi Z, Yari K, Rahimi Z. Matrix metalloproteinase-9 -1562T allele and its combination with MMP-2 -735 C allele are risk factors for breast cancer. Asian Pac J Cancer Prev. 2015;16(3):1175-9. doi: 10.7314/apjcp.2015.16.3.1175. PMID: 25735351.
Okada R, Naito M, Hattori Y, Seiki T, Wakai K, Nanri H, Watanabe M, Suzuki S, Kairupan TS, Takashima N, Mikami H, Ohnaka K, Watanabe Y, Katsuura-Kamano S, Kubo M, Hamajima N, Tanaka H; Japan Multi-institutional Collaborative Cohort Study Group. Matrix metalloproteinase 9 gene polymorphisms are associated with a multiple family history of gastric cancer. Gastric Cancer. 2017 Mar;20(2):246-253. doi: 10.1007/s10120-016-0608-2. Epub 2016 Apr 6. PMID: 27053167.